Anemia of chronic disorders in systemic autoimmune diseases

Haematologica

Volumn 82, Issue 3, 1997, Pages 375-381

  Bertero, Maria Tiziana ^a,b   Caligaris Cappio, Federico ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Cattedra di Immunologia Clinica   (Italy)

Author keywords

Anemia; Autoimmunity; Chronic disorders; Cytokines; Erythropoietin; Soluble transferrin receptor

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; FERRITIN; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; IRON; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ANEMIA; AUTOIMMUNITY; CHRONIC DISEASE; ERYTHROPOIESIS; HELPER CELL; HUMAN; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; IRON METABOLISM; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOCYTE PROLIFERATION; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ACUTE-PHASE REACTION; ANEMIA; AUTOIMMUNE DISEASES; CHRONIC DISEASE; CYTOKINES; ERYTHROPOIESIS; ERYTHROPOIETIN; HUMANS; IRON; IRON OVERLOAD; LYMPHOCYTE SUBSETS; NITRIC OXIDE; RETICULOENDOTHELIAL SYSTEM;

EID: 0031467102     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Means RTJr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80:1639-47.
2. Gudbjornsson B, Hallgren R, Wide L, Birgegard G. Response of anemia in rheumatoid arthritis to treatment with subcutaneous recombinant human erythropoietin. Ann Rheum Dis 1992; 51:747-52.
3. Feelders RA, Vreugdenhil G, Manger B, van Eijk HG, Swaak AJG. Serum transferrin receptor levels in anaemia of rheumatoid arthritis and effects of iron chelation treatment. EurJ Haematol 1994; 52: 61.
4. Noé G, Augustin J, Hausdorf S, Rich IN, Kubanek B. Serum erythropoietin and transferrin receptor levels in patients with rheumatoid arthritis. Clin Exp Rheumatol 1995; 13:445-51.
5. Cazzola M, Beguin Y. New tools for clinical evaluation of erythron function in man. Br J Haematol 1992; 80:278-84.
6. Beguin Y, Clemons GK, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993; 81:1067-76.
7. Huebers MA, Beguin Y, Pootrakul P, Einspahr D, Finch CA. Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood 1990; 75:102-7.
8. Erslev AJ. Anemia of chronic disease. In: Beutler E, Lichtman MA, Coller BS, Kipps TH, eds. Williams' Hematology. New York: McGraw-Hill, 1995. p. 518-24.
9. Kushner I, Rzewnicki DL. The acute phase response: general aspects. Clin Rheumatol 1994; 8:513-30.
10. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86:1243-54.
11. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095-147.
12. Introna M, Vidai Alles V, Castellano M, et al. Cloning of Mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood 1996; 87:1862-72.
13. Schultz DR, Arnold PI. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein and fibrinogen. Semin Arthritis Rheum 1990; 20:129-47.
14. Van Leeuwen MA, Van Rijswijk MH. Acute phase proteins in the monitoring of inflammatory disorders. Clin Rheumatol 1994; 8:531-52.
15. Kent S, Weinberg ED, Stuart-Macadam P. The etiology of the anemia of chronic disease and infection. J Clin Epidemiol 1994; 47:23-33.
16. Djeha A, Pérez-Arellano JL, Brock JH. Tranferrin synthesis by mouse lymph node and peritoneal macrophages: iron content and effect on lymphocyte proliferation. Blood 1993; 81:1046-50.
17. Gordon C, Emery P. Cytokines and the acute phase response in SLE. Lupus 1993; 2:345-47.
18. Ozoran K, Aydintug O, Tokgoz G, Duzgun N, Tutkak H. Serum levels of interleukin-8 in patients with Behcet's disease. Ann Rheum Dis 1995; 54:610.
19. Vitali C, Bencivelli W, Isenberg DA, and the European Consensus Study Group for Disease Activity in SLE: disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II, Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheum 1992; 10:541-47.
20. Ter Borg EJ, Horst G, Limburg PC, Rijswijk MH, Kallenberg CGM. C-reative protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol 1990; 17:1642-48.
21. Baumann H, Schendel P. Interleukin-11 regulates the hepatic expression of the same plasma protein genes as interleukin-6. J Biol Chem 1991; 266:20424-7.
22. Reid CDL, Prouse PJ, Baptista LC, Gumpel JM, Chanarin I. The mechanism of the anaemia in rheumatoid arthiritis: effects of bone marrow adherent cells and of serum on in vitro erythropoiesis. Br J Haematol 1984; 58:607-11.
23. Keller JR, Sing GK, Ellingsworrth LR, Ruscetti SK, Ruscetti FW. Two forms of transforming growth factor-β are equally important selective growth inhibitors of early murine hematopoiesis. Ann NY Acad Sci 1990; 593:172-6.
24. Hino M, Tojo A, Miyazono K, Urabe A, Takaku F. Effects of β transforming growth factors on hematopoietic progenitor cells. Br J Haematol 1988; 70:143-8.
25. Means RT, Krantz SB. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest 1993; 91:416-9.
26. Means RT, Dessypris EN, Krantz SB. Inhibition of human erythroid colony-forming units by interteukin-1 is mediated by γ interferon. J Cell Physiol 1992; 150:59-64.
27. Furmanski P, Johnson CS. Macrophage control of normal and leukemic erythropoiesis. Identification of the macrophage derived erythroid suppressing activity as interleukin-1 and the mediator of its effect as tumor necrosis factor. Blood 1990; 75:2328-34.
28. Neta R, Sztein MB, Oppenheim JJ, Gillis S, Douches SD. The in vivo effects of interleukin-1. Bone marrow cells are induced to cycle after administration of interleukin-1. J Immunol 1987; 139:1861-6.
29. Moreb J, Zucali JR, Weiner RS. The role of interleukin 3 and interleukin 6 in the protection from 4-hydroperoxycyclophosphamide and the proliferation of early human hematopoietic progenitor cells. Exp Hematol 1989; 17:1022-8.
30. Neta R, Vogel SN, Plocinski JM, et al. In vivo modulation with anti IL-1 receptor (p80) antibody 35 F5 of the response to IL-1. Blood 1990; 76:57-62.
31. Henricson BE, Neta R, Vogel SN. An interleukin-1 receptor antagonist blocks lipopolysaccharide-induced colony stimulating factor production and early endotoxin tolerance. Infect Immun 1991; 59: 1188-95.
32. Zucali JR, Moreb J, Gibbons W, et al. Radioprotection of hematopoietic stem cells by interleukin-1. Exp Hematol 1994; 22:130-5.
33. Neta R, Oppenheim JJ, Wang JM, Snapper CM, Moorman MA, Dubois CM. Synergy of IL-1 and stem cell factor in radioprotection of mice is associated with IL-1 up-regulation of mRNA and protein expression for c-kit on bone marrow cells. J Immunol 1994; 153: 1536-43.
34. Muta K, Krantz SB, Bondurant MC, Wickrema A. Distinct roles of erythropoietin, insulin-like growth factor I, and stem cell factor in the development of erythroid progenitor cells. J Clin Invest 1994; 94: 34-43.
35. Brennan FM, Maini RN, Feldmann M. TNFα - a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992; 31:293-8.
36. Maury CPJ, Andersson LC, Teppo AM, Partanen S, Juvonen E. Mechanism of the anaemia in rheumatoid arthritis: demonstration of raised interleukin 1β concentrations in anaemic patients and of interleukin 1-mediated suppression of normal erythropoiesis and proliferation of human erythroleukemia (HEL) cells in vitro. Ann Rheum Dis 1988; 47:972-5.
37. Elliott MJ, Maini RN, Feldmann M, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1105-10.
38. Maini RN, Elliott M, Brennan FM, et al. Monoclonal anti-TNF-alpha antibody as a probe of pathogenesis and therapy of rheumatoid arthritis. Immunol Rev 1995; 144:195-223.
39. Suzuki H, Takemura H, Kashiwagi H. Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Enhanced production by monocytes and correlation with disease activity. Arthritis Rheum 1995; 38:1055-9.
40. Dinarello CA. Modalities for reducing interleukin 1 activity in disease. Immunol Today 1993; 14:260-4.
41. Otsuka T, Nagasawa K, Harada M, Niho Y. Bone marrow microenvironment of patients with systemic lupus erythematosus. J Rheumatol 1993; 20:967-71.
42. Vreugdenhil G, Lowenberg B, van Eijk HG, Swaak AJG. Anaemia of chronic disease in rheumatoid arthritis: raised serum interleukin-6 (IL-6) levels and the effects of IL-6 and anti-IL-6 on in vitro erythropoiesis. Rheumatol Int 1990; 10:127-32.
43. Houssiau FA, Devogelaer JP, Van Damme J, Nagant de Deuxchaisnes C, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31:784-9.
44. Van Gameren MM, Willemse PHB, Mulder NH, et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 1994; 84:1434-41.
45. Cazzola M, Ponchio L, De Benedetti F, et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 1996; 87:4824-30.
46. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991; 147:117-23.
47. Swaak AJG, Sintnicolaas C, Meijer C, Smeenk RT. Observations on the interleukin-6 and acute phase protein profiles in the disease course of patients with lupus erythematosus. Lupus 1992; 1:151-5.
48. Spronk PE, Ter Borg EJ, Limburg PC, Kallenberg CGM. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clin Exp Immunol 1992; 90:106-10.
49. Kranrz SB. Erythropoietin. Blood 1991; 77:419-34.
50. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79:1987-94.
51. Noe' G, Augustin J, Hausdorf S, Rich IN, Kubanek B. Serum erythropoietin ana transferrin recepetor levels in patients with rheumatoid arthritis. Clin Exp Rheumatol 1995; 13:445-51.
52. Kalunian KC. Definition, classification, and activity indices. In: Wallace DJ, Hanh BH, eds. Dubois' lupus erythematosus. Philadelphia:Lea & Febiger, 1993. p. 58-63.
53. Lacombe C, De Silva JL, Bruneval P, et al. Peritubular cells are the site of eythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 1988; 81:620-23.
54. Caligaris-Cappio F, Bergui L, Tesio L, Ziano R, Camussi G. HLA-DR+ T cells of the Leu 3 (helper) type infiltrate the kidneys of patients with lupus erythematosus. Clin Exp Immunol 1985; 59: 185-9.
55. Yamamoto T, Nagase M, Hishida A, Honda N. Interstitial inflammatory and chronic tubulointerstitial lesions in lupus nephritis: comparison with those in IgA nephropathy. Lupus 1993; 2:261-8.
56. Schooley JC, Kullgren B, Allison AC. Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemias. Br J Haematol 1987; 67:11-7.
57. Weiss G, Wachter H, Fuchs D. Linkage of cell-mediated immunity to iron metabolism. Immunol Today 1995; 16:495-500.
58. Means RT, Krantz SB. Inhibition of human erythroid colony-forming units by g interferon can be corrected by recombinat human erythropoietin. Blood 1991; 78:2564-7.
59. Denz H, Fuchs D, Hubert H, et al. Correlation between neopterin, interferon-gamma and haemoglobin in patients with haematological disordes. Eur J Haematol 1990; 44:186-9.
60. Sherwood JB, Goldwasser E, Chilcote R, Carmichael LD, Nagel RL. Sickle cell anemia patients have low erythropoietin levels for their degree of anemia. Blood 1986; 67:46-9.
61. Asherson RA, Kant KS. Antiphospholipid antibodies and the kidney. J Rheumatol 1993; 20:1268-72.
62. Lacombe C. Resistance to erythropoietin. N Engl J Med 1996; 334: 660-2.
63. Meijer C, Huysen V, Smeenk RTJ, Swaak AJG. Profiles of cytokines (TNFα and IL-6) and acute phase proteins (CRP and α 1AG) related to the disease course in patients with systemic lupus erythematosus. Lupus 1993; 2:359-65.
64. Greendyke RM, Sharma K, Gifford FR. Serum levels of erythropoietin and selected other cytokines in patients with anemia of chronic disease. Am J Clin Pathol 1994; 101:338-41.
65. Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 1996; 334:619-23.
66. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. Brief report: autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996; 334:630-3.
67. Thorson JA, Smith KM, Gomez F, Naumann PW, Kemp JD. Role of iron in T cell activation: TH1 clones differ from TH2 clones in their sensitivity to inhibitor of DNA synthesis caused by IgG Mabs against the transferrin receptor and the iron chelator deferoxamine. Cell Immunol 1991; 134:126-37.
68. Weiss G, Werner-Felmayer G, Werner ER, Grunewald K, Wachter H, Hentze MW. Iron regulates nitric oxide synthase activity by controlling nuclear transcription. J Exp Med 1994; 180:969-76.
69. Farrell AJ, Blake DR. Nitric oxide. Ann Rheum Dis 1996; 55:7-20.
70. Kolb H, Kolb-Bachofen V. Nitric oxide: a pathogenetic factor in autoimmunity. Immunol Today 1992; 13:157-60.
71. Drapier JC, Hirling H, Wietzerbin J, Kaldy P, Kuhn LC. Biosynthesis of nitric oxide activates iron regulatory factor in macrophages EMBOJ 1993; 12:3643-50.
72. Weiss G, Coossen B, Doppler W, et al. Translational regulation via iron responsive elements by nitric oxide/NO-synthase pathway EMBO J 1993; 12:3651-7.
73. Melfors O, Hentze MW. Iron regulatory factor - the conductor of cellular iron regulation. Blood Rev 1993; 7:251-8.
74. Klausner R, Rouault TA, Harford JB. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell 1993; 72:19-28.
75. Kobune M, Kohgo Y, Kato J, Miyazaki E, Niitsu Y. Interleukin-6 enhances hepatic transferrin uptake and ferritin expression in rats. Hepatology 1994; 19:1468-75.
76. Fairbanks VF, Beutler E. Iron metabolism. In: Beutler E, Lichtman MA, Coller BS, Kipps TH, eds. Williams' Hematology. New York: McGraw-Hill, 1995. p. 369-80.
77. Fuchs D, Hausen A, Reibnegger G, et al. Immune activation and the anemia associated with chronic inflammatory disorders. Eur J Haematol 1991; 46:65-70.
78. Romagnani S. Lymphokine production by human T cells in disease states. Ann Rev Immunol 1994; 12:227-58.
79. Krantz SB. Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci 1994; 307:353-9.
80. Martini A, Ravelli A, Di Fuccia G, Rosti V, Cazzola M, Barosi G. Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet 1994; 344:1052-4.
81. Means RT Jr, Olsen NJ, Krantz SB, et al. Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: clinical and in vitro studies. Arthritis Rheum 1989; 32:638-42.
82. Pincus T, Olsen NJ, Russell IJ, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. AmJ Med 1990; 89:161-8.
83. Peeters HRM, Jongen-Lavrencic M, Vreugdenhil G, Swaak AJG. Effect of recombinant human erythropoirtin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial. Ann Rheum Dis 1996; 55:739-44.
84. Barosi G. Inadequate erythropoietin response to anemia: definition and clinical relevance. Ann Hematol 1994; 68:215-23.
85. Barosi G, Cazzola M, De Vincentiis A, Grossi A, Tura S. Guidelines for the use of recombinant human erythropoietin. Haematologica 1994; 79:526-33.
86. Musto P, Modoni S, Alicino G, et al. Modification of erythropoiesis in myelodysplastic sundromes treated with recombinant human erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes. Haematologica 1994; 79:493-9.
87. Balleari E, Gatti AM, Mareni C, Massa G, Marmont AM, Ghio R. Recombinant human erythropoietin for long-term treatment of anemia in paroxysmal nocturnal hemoglobinuria. Haematologica 1996; 81:143-7.